UPCC 16215 Genomic, Epigenetic, Proteomic, Metabolomic and Immunologic Characterization of Primary Liver Cancer and Liver Cancer Cells Surviving Locoregional Therapy

Enrolling By Invitation
99 years or below
All
Phase N/A
150 participants needed
1 Location

Brief description of study

To acquire baseline and serial HCC cancer core biopsy samples in order to characterize the epigenetic, proteomic, metabolomic and immunologic profile of hepatocellular carcinoma cells surviving TACE. See section 2 of full protocol. See section 3.2 full protocol. See section 3.3 full protocol.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 22 Apr 2026. Study ID: 15-0206
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator